Standard BioTools to Announce Third Quarter Financial Results on November 4, 2025

Standard BioTools Inc. (NASDAQ: LAB) today announced that it will publish third quarter 2025 financial results on Tuesday, November 4, 2025, after U.S. market close.

About Standard BioTools Inc.

Standard BioTools Inc. (Nasdaq: LAB), has an established portfolio of essential, standardized next-generation technologies that help biomedical researchers develop better medicines faster. As a leading solutions provider, the company provides reliable and repeatable insights in health and disease using its proprietary SomaScan, mass cytometry and microfluidics technologies, which help transform scientific discoveries into better patient outcomes. Standard BioTools works with leading academic, government, pharmaceutical, biotechnology, plant and animal research and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology and immunotherapy. Learn more at standardbio.com or connect with us on X, Facebook ^® , LinkedIn, and YouTube™.

Limited Use Label License and other terms may apply: standardbio.com/legal/salesterms .
Patent and License Information: standardbio.com/legal/notices .
©2025 Standard BioTools Inc. All rights reserved.

Standard BioTools products are provided for Research Use Only. Not for use in diagnostic procedures.

Investor Contact:
ir@standardbio.com

News Provided by GlobeNewswire via QuoteMedia

Standard BioTools LAB NGS:LAB biotech investing

LAB

Spartan Metals Reports Significant Silver-Antimony-Copper Assays with Grades up to 1,927 g/t Ag, 0.67% Sb, and 1.83% Cu from Past Producing Antelope Mine, Nevada

Spartan Metals Corp. (TSXV: W,OTC:SPRMF) (OTCQB: SPRMF) (FSE: J03) ("Spartan" or the "Company") is pleased to announce assay results from recent sampling conducted at its past producing Antelope Mine within the Rees Claims at its 100% owned Eagle Project, Nevada (Figure 1). Highlights: Backpack... Keep Reading...

Emperor Metals Returns 15.0 Meters of 61.5 g/t Gold Including 2.4 Meters of 369.6 g/t Gold

Visible gold observed in multiple zones within the intercept.

Emperor Metals Inc. (CSE: AUOZ) (OTCQB: EMAUF) (FSE: 9NH) ("Emperor") is pleased to report on the recent assay release of high-grade gold in DQ26-20 as well as progress of its 2026 exploration campaign at its Duquesne West Project, integrating +15,000 meters of new drilling with 8,000 meters of... Keep Reading...

Brixton Metals Drills 906 g/t Silver over 4.3 m, including 1,329 g/t Silver over 1.8 m, all within 23.7 m of 206.6 g/t Silver at its Langis Project And 4.95 m of 493 g/t silver, including 1,798 g/t silver over 1.0 m

Brixton Metals Corporation (TSX-V: BBB, OTCQX: BBBXF) (the "Company" or "Brixton") is pleased to announce results from its ongoing exploration at the wholly owned Langis Silver Project, located in the historic silver mining camp of Cobalt, Ontario, Canada. The 2026 drill campaign marks a... Keep Reading...

Standard BioTools to Announce Third Quarter Financial Results on November 4, 2025

Spartan Metals Reports Significant Silver-Antimony-Copper Assays with Grades up to 1,927 g/t Ag, 0.67% Sb, and 1.83% Cu from Past Producing Antelope Mine, Nevada

Spartan Metals' Exploration Program Confirms Tungsten Skarn Discoveries at past Producing Mine at Eagle Project, Nevada

Emperor Metals Returns 15.0 Meters of 61.5 g/t Gold Including 2.4 Meters of 369.6 g/t Gold

Visible gold observed in multiple zones within the intercept.

Brixton Metals Drills 906 g/t Silver over 4.3 m, including 1,329 g/t Silver over 1.8 m, all within 23.7 m of 206.6 g/t Silver at its Langis Project And 4.95 m of 493 g/t silver, including 1,798 g/t silver over 1.0 m

Spartan Metals Discovers Two New Tungsten-Silver Veins at Tungstonia

Lexaria's Human Study GLP-1-H26-7 Has Begun Dosing on Schedule

Lexaria's Animal Study GLP-1-A26-1 Has Begun Dosing on Schedule

GLP-1 'Arms Race' Intensifies as the Addressable Markets Continue to Expand

GLP-1 "Arms Race" Intensifies as the Addressable Markets Continue to Expand

Lexaria's Animal Study Examining Next-Generation GLP-1 drugs is Underway.

Lexaria's Animal Study Examining Next-Generation GLP-1 drugs is Underway

Latest News

Lexaria's Human Study GLP-1-H26-7 Has Begun Dosing on Schedule

BriaCell Partners with Uneedle for Scalable Microneedle Administration of Bria-IMT

Lexaria's Animal Study GLP-1-A26-1 Has Begun Dosing on Schedule

Interactive Chart

Latest Press Releases

Western Uranium & Vanadium Announces Results of 2026 AGM

Premier American Uranium Reports Results Following Annual General and Special Meeting of Shareholders

Nuvau Winter Drilling at Thundermine Returns 5.28 g/t Au over 6.1 m, Including 7.22 g/t Au over 3.1 m

Update Strengthens Cu-Au Targets, Glava & Torsby West

Related News

Western Uranium & Vanadium Announces Results of 2026 AGM

Top 5 Canadian Mining Stocks This Week: Grande Portage Resources Gains 32 Percent

Titan Mining to Partner with US Army for Graphite-processing Facilities

Premier American Uranium Reports Results Following Annual General and Special Meeting of Shareholders

Nuvau Winter Drilling at Thundermine Returns 5.28 g/t Au over 6.1 m, Including 7.22 g/t Au over 3.1 m

Update Strengthens Cu-Au Targets, Glava & Torsby West

Top 5 Australian Mining Stocks This Week: Lakes Blue Energy Rises as Wombat Gas Field Progresses

TOP STOCKS